Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2DM)

ID Number 10-1116

Principal Investigator(s)
Robert Rosenson

Department(s) or Division(s)


Acute coronary syndrome (ACS) continues to be a major medical challenge both because of its high incidence and the high rate of recurrent events in the months following the initial event. It is well established that patients with Type 2 diabetes mellitus (T2D) have an increased cardiovascular risk compared with patients without diabetes. As then expected, patients with diabetes are at particularly high risk of future recurrent events and their overall prognosis after ACS is much worse compared to patients without diabetes.

The purpose of this research is to study a drug called Aleglitazar. Aleglitazar is a drug which affects blood sugar levels and cholesterol levels.  Aleglitazar is considered investigational (experimental) in this study, because it has not been approved by the US Food and Drug Administration (FDA). Taking the study drug may improve blood sugar levels. It may also increase good cholesterol (HDL-C) levels and decrease triglyceride levels. Even though these levels may improve, at this time, it is not known if the study drug will improve cardiovascular disease.

Contact Information
Michael Manalang, MD
(212) 659-9638

Recruiting Patients: Yes